Document is current
Any future updates will be listed below
-
Authors
Yagdiran, Ayla https://orcid.org/0000-0002-1723-5995
Paul, Gregor https://orcid.org/0000-0002-1075-4362
Meyer-Schwickerath, Charlotte https://orcid.org/0000-0001-6711-6516
Scheder-Bieschin, Justus https://orcid.org/0000-0001-5145-8992
Tobys, David https://orcid.org/0000-0001-5528-6059
Kernich, Nikolaus https://orcid.org/0000-0001-8540-5725
Eysel, Peer https://orcid.org/0000-0002-9929-3370
Jung, Norma https://orcid.org/0000-0002-5740-0772
-
Funding
Funding for this research was provided by:
Universitätsklinikum Köln
- License Information
-
More Information
Article History
Received: 31 January 2023
Accepted: 14 March 2023
First Online: 18 April 2023
Declarations
:
: Each author certifies that there are no funding or commercial associations (consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article related to the author or any immediate family members except for NJ. NJ has received lecture fees from Gilead, Infectopharm, MSD, Bayer; Medacta and Labor Stein and travel grants from Pfizer, Gilead, Basilea, Correvio, Pfizer and Novartis and grants from an observational study from Infectopharm.
: The study was approved by the ethics committee of our institution (file number: 09-182) and complies with the principles of the Declaration of Helsinki (1996).
